Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

🇨🇳 Laotian Times (CN) —
Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

AI Summary

Vcare PharmaTech has received marketing approval for Eratrectinib, a next-generation TRK inhibitor developed independently targeting NTRK gene fusions found in adults and pediatric solid tumors. This advanced biotech drug represents a significant development in cancer treatment.

NANJING, China, June 5, 2026 /PRNewswire/ — NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, more than 229 fusion partner genes have […]

Markets Deals Health AI & Tech Vcare PharmaTech Eratrectinib TRK inhibitor NTRK gene fusion cancer treatment biotech drug approval

Read original source →